Autopsy report · NCT03630640

Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation

“Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding partner halted enrollment at that time to meet contractual obligations”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 4 years 10 months before it stopped.
• 43 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Assistance Publique - Hôpitaux de Paris

Sponsor type

University, hospital or other

Conditions

Hepatocellular Carcinoma

Interventions

Nivolumab Injection [Opdivo]

Participants

43

Sites

1

Countries

France

Trials that died the same way

• Liking Adaptation to Beverages of Varying Sweetness Levels After Prolonged Exposure
  “Sponsor decision to stop study due to COVID-19 pandemic” (78% match in meaning)
• Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
  “The study was prematurely terminated by the Sponsor based on difficulties in meeting enrollment goals, especially during the COVID-19 pandemic, and not for reasons relating to any concerns regarding quality, safety, or efficacy.” (78% match in meaning)
• Assessment of the Utility of BIOMONITOR to Identify Atrial Fibrillation (AF) in Ablation Candidates Using Precise AF Detection
  “This study was terminated by the sponsor since study timelines were extended significantly due to slow enrollment, partly influenced by the COVID-19 pandemic.” (78% match in meaning)
• The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study
  “Due to difficulty in recruiting patients, the Sponsor decided to prematurely stop the study” (77% match in meaning)
• Study of Focal Airway Disease in Asthma Using Image Guided Bronchoscopy
  “The restrictions on research imposed for the COVID-19 pandemic prevented us from launching study recruitment and visits. At this stage our funding is not sufficient to allow us to enroll sufficient numbers of patients so we will close the study.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.